KTRA
Kintara Therapeutics, Inc. [KTRA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KTRA Stock Summary
Top 10 Correlated ETFs
KTRA
Top 10 Correlated Stocks
KTRA
In the News
KTRA Financial details
Company Rating
Neutral
Market Cap
6.92M
Income
-10.55M
Revenue
0
Book val./share
-0.04
Cash/share
0.15
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.02
Forward P/E
-
PEG
0
P/S
-
P/B
-0.12
P/C
0.71
P/FCF
-0.07
Quick Ratio
0.06
Current Ratio
0.23
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.85
EPS next Y
-
EPS next Q
-
EPS this Y
-61.07%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-86.05%
-
-
-
-
SMA20
33.33%
SMA50
-7.69%
SMA100
-65.71%
Inst Own
237.47%
Inst Trans
0.66%
ROA
-876%
ROE
-569%
ROC
7.15%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.081-5.98
52W High
-
52W Low
-
RSI
46.73
Rel Volume
0.11
Avg Volume
15.01M
Volume
1.67M
Perf Week
-19.06%
Perf Month
11.97%
Perf Quarter
-97.27%
Perf Half Y
-97.13%
-
-
-
-
Beta
0.595
-
-
Volatility
0.01%, 0.02%
Prev Close
2.7%
Price
0.1066
Change
-0.28%
KTRA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
| Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -143.87 | -48.39 | -74.02 | -23.22 | -9.04 | |
| Operating cash flow per share | -122.88 | -37.95 | -36.43 | -20.94 | -7.32 | |
| Free cash flow per share | -122.88 | -37.95 | -36.44 | -20.94 | -7.47 | |
| Cash per share | 72.22 | 11.45 | 20.35 | 12.09 | 0.95 | |
| Book value per share | 38.21 | 1.26 | 20.44 | 12.11 | 0.45 | |
| Tangible book value per share | 37.98 | 1.25 | 20.44 | 12.11 | 0.45 | |
| Share holders equity per share | 38.21 | 1.26 | 20.44 | 12.11 | 0.45 | |
| Interest debt per share | 0 | 0 | 0.05 | 0.01 | 0 | |
| Market cap | 3.3M | 7.19M | 58.76M | 13.54M | 6.53M | |
| Enterprise value | -423.21K | 4.79M | 48.22M | 1.76M | 4.99M | |
| P/E ratio | -0.44 | -0.71 | -1.53 | -0.6 | -0.45 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -0.52 | -0.91 | -3.12 | -0.66 | -0.55 | |
| PFCF ratio | -0.52 | -0.91 | -3.11 | -0.66 | -0.54 | |
| P/B Ratio | 1.67 | 27.3 | 5.55 | 1.15 | 8.93 | |
| PTB ratio | 1.67 | 27.3 | 5.55 | 1.15 | 8.93 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0.05 | -0.68 | -2.23 | -0.08 | -0.34 | |
| EV to operating cash flow | 0.07 | -0.6 | -2.56 | -0.09 | -0.42 | |
| EV to free cash flow | 0.07 | -0.6 | -2.56 | -0.09 | -0.41 | |
| Earnings yield | -2.25 | -1.41 | -0.65 | -1.67 | -2.24 | |
| Free cash flow yield | -1.92 | -1.1 | -0.32 | -1.51 | -1.85 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0.43 | 0.34 | 0.49 | 0.52 | 0.1 | |
| Current ratio | 1.94 | 1.07 | 4.24 | 3.32 | 1.06 | |
| Interest coverage | 0 | 0 | -833.31 | -1.62K | 0 | |
| Income quality | 0.79 | 0.87 | 0.49 | 0.9 | 0.81 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0.02 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | -0.25 | 0 | -3.87 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 351.69 | 37.04 | 184.5 | 79.54 | 9.58 | |
| ROIC | -4.06 | -29.82 | -2.05 | -1.92 | -20.05 | |
| Return on tangible assets | -1.84 | -3.44 | -2.83 | -1.42 | -3.68 | |
| Graham Net | 32.41 | -1.09 | 14.63 | 7.83 | -1.06 | |
| Working capital | 1.96M | 176.16K | 9.01M | 9.27M | 188K | |
| Tangible asset value | 1.96M | 261.11K | 10.58M | 11.8M | 731K | |
| Net current asset value | 1.96M | 176.16K | 8.83M | 9.11M | 22K | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 32.85K | 17.79K | 4.7K | 0 | 0 | |
| Average payables | 1.61M | 1.88M | 2.12M | 2.74M | 3.03M | |
| Average inventory | 0 | 46.85K | 46.85K | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 38.95K | 73.4K | 25.31K | 19.89K | 16.94K | |
| Days of inventory on hand | 0 | 3.42K | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.01 | 0 | 0.01 | 0.02 | 0.02 | |
| Inventory turnover | 0 | 0.11 | 0 | 0 | 0 | |
| ROE | -3.77 | -38.4 | -3.62 | -1.92 | -20.04 | |
| Capex per share | 0 | 0 | -0.02 | 0 | -0.14 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q2
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -2.07 | -1.92 | -1.97 | -1.72 | -0.24 | |
| Operating cash flow per share | -1.32 | -1.09 | -0.89 | -0.77 | -0.49 | |
| Free cash flow per share | -1.32 | -1.09 | -0.89 | -0.77 | -0.49 | |
| Cash per share | 2.97 | 1.81 | 0.91 | 0.13 | 0.15 | |
| Book value per share | 4.02 | 2.25 | 0.43 | -1.18 | -0.04 | |
| Tangible book value per share | 4.02 | 2.25 | 0.43 | -1.18 | -0.04 | |
| Share holders equity per share | 4.02 | 2.25 | 0.43 | -1.18 | -0.04 | |
| Interest debt per share | -0.03 | -0.02 | 0 | 0 | 0 | |
| Market cap | 11.32M | 5.93M | 6.82M | 6.94M | 735.56K | |
| Enterprise value | 6.45M | 2.89M | 5.28M | 6.72M | 77.56K | |
| P/E ratio | -0.83 | -0.46 | -0.51 | -0.59 | -0.18 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -5.24 | -3.25 | -4.52 | -5.27 | -0.35 | |
| PFCF ratio | -5.24 | -3.25 | -4.52 | -5.27 | -0.34 | |
| P/B Ratio | 1.72 | 1.57 | 9.33 | -3.43 | -4.49 | |
| PTB ratio | 1.72 | 1.57 | 9.33 | -3.43 | -4.49 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -1.85 | -0.88 | -1.58 | -2.28 | -0.08 | |
| EV to operating cash flow | -2.98 | -1.58 | -3.5 | -5.11 | -0.04 | |
| EV to free cash flow | -2.98 | -1.58 | -3.5 | -5.11 | -0.04 | |
| Earnings yield | -0.3 | -0.54 | -0.49 | -0.43 | -1.39 | |
| Free cash flow yield | -0.19 | -0.31 | -0.22 | -0.19 | -2.91 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 1.4 | 0.93 | 0.46 | 0.07 | 0.66 | |
| Current ratio | 2.83 | 2.16 | 1.06 | 0.23 | 0.63 | |
| Interest coverage | 77.76 | 89.22 | 0 | 0 | 0 | |
| Income quality | 0.63 | 0.56 | 0.45 | 0.44 | 2.07 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | -1.33 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 13.69 | 9.86 | 4.38 | 6.76 | 0.45 | |
| ROIC | -0.52 | -0.86 | -4.58 | 1.55 | 6.21 | |
| Return on tangible assets | -0.34 | -0.48 | -0.84 | -2.01 | -0.54 | |
| Graham Net | 0.95 | 0.06 | -1.01 | -1.91 | -0.3 | |
| Working capital | 5.94M | 3.23M | 188K | -2.55M | -684K | |
| Tangible asset value | 6.6M | 3.79M | 731K | -2.03M | -164K | |
| Net current asset value | 5.86M | 3.06M | 22K | -2.72M | -863K | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 51.5K | |
| Average payables | 2.82M | 2.65M | 2.7M | 2.89M | 2.36M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 16.15K | 15.66K | 16.7K | 17.99K | 10.33K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.52 | -0.85 | -4.56 | 1.46 | 6.24 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
KTRA Frequently Asked Questions
What is Kintara Therapeutics, Inc. stock symbol ?
Kintara Therapeutics, Inc. is a US stock , located in San diego of Ca and trading under the symbol KTRA
What is Kintara Therapeutics, Inc. stock quote today ?
Kintara Therapeutics, Inc. stock price is $0.1066 today.
Is Kintara Therapeutics, Inc. stock public?
Yes, Kintara Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 15.01M
- Market Capitalization 6.92M
- Employee 2
- CEO Mr. Robert E. Hoffman B.B.A., CPA
- Headquarters San Diego,CA,US
- IPO Date 2013-02-22
-
Website
https://www.kintara.com 
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
